Scoring System Based on Tumor Markers and Child-Pugh Classification for HCC Patients who Underwent Liver Resection
|
|
- Stuart Matthews
- 5 years ago
- Views:
Transcription
1 Scoring System Based on Tumor Markers and Child-Pugh Classification for HCC Patients who Underwent Liver Resection SHIGEKI NAKAGAWA 1, HIROMITSU HAYASHI 1, HIDETOSHI NITTA 1, HIROHISA OKABE 1, KEITA SAKAMOTO 1, TAKAAKI HIGASHI 1, HIDEYUKI KUROKI 1, KATSUNORI IMAI 1, DAISUKE HASHIMOTO 1, YASUO SAKAMOTO 1,2, AKIRA CHIKAMOTO 1, TORU BEPPU 1,2 and HIDEO BABA 1 1 Department of Gastroenterological Surgery, Graduate School of Life Sciences, Kumamoto University, Kumamoto, Japan; 2 Department of Multidisciplinary Treatment for Gastroenterological Cancer, Kumamoto University Hospital, Kumamoto, Japan Abstract. Background: The long-term prognosis of hepatocellular carcinoma (HCC) patients after hepatic resection (HR) remains poor because of limited liver function and frequent recurrences. We created a prognostic system of HCC based on tumor markers and Child-Pugh classification. Patients and Methods: This study investigated 427 HCC patients and three tumor markers (alphafetoprotein (AFP), Lens culinaris agglutinin-reactive fraction of AFP (AFP-L3), des-γ -carboxyprothrombin (DCP)) in relation to Child-Pugh classification by the stepwise Cox regression model for establishing a tumor marker staging (TMS). Results: The TMS shows four levels (0/1/2/3) with 5-year recurrence rate of each stage of 76.7, 72.3, 80.9 and 100%, respectively, and 5-year overall survival of 77.0, 68.7, 52.1 and 28.9%, respectively. This TMS appears to be a better model to predict the recurrence and survival of HCC patients after hepatectomy than only the number of positive tumor markers. Conclusion: TMS is a useful staging system to evaluate biological status and background liver function. Hepatocellular carcinoma (HCC) is a common malignancy worldwide, especially in Asian countries with an increasing incidence in Western countries (1, 2). Development of devices for diagnosis, such as computed tomography (CT), Correspondence to: Professor Hideo Baba, MD, Ph.D., Department of Gastroenterological Surgery, Graduate School of Life Sciences, Kumamoto University, Honjo, Kumamoto , Japan. Tel: , Fax: , hdobaba@ kumamoto-u.ac.jp Key Words: Hepatocellular carcinoma (HCC), alpha-fetoprotein (AFP), Lens culinaris agglutinin-reactive fraction of AFP (AFP-L3), des-γ-carboxyprothrombin (DCP), tumor marker. angiography, vascular imaging, ultrasonography and magnetic resonance imaging (MRI) enables for detection of early stages of HCC. The development of therapeutic modalities, including liver transplantation, hepatic resection, trans-arterial chemoembolization and localized ablation therapy has improved the prognosis of HCC patients (3-5). Nevertheless, short- and long-term prognoses remain a difficult task to accomplish. For the diagnosis of HCC, three tumor markers, alphafetoprotein (AFP), Lens culinaris agglutinin-reactive fraction of AFP (AFP-L3) and des-γ-carboxyprothrombin (DCP), are usually being examined in addition to the diagnostic imaging. These tumor markers are useful tools not only for the diagnosis but also for the evaluation of the the malignant potential of HCC and prediction of prognosis (6-10). Recently, the examination of all three tumor markers was proven useful in predicting the prognosis of curativelyresected HCC (11-13). To predict the prognosis of HCC patients, the tumor-nodemetastasis (TMN) staging, which proposed by the International Union against Cancer (UICC) (14) or the Liver Cancer Study Group of Japan are being followed. However, new staging systems that combined tumor malignancy and liver function, such as the Cancer of the Liver Italian Program (CLIP) (15, 16) and Japan Integrated Staging (JIS) (17) system, have been created and clarified the usefulness to predict the prognosis of HCC patients. Not only tumor factors, such as TNM staging and tumor markers, but also liver function is also important to define the prognosis (18) in HCC patients as HCC may occur from cirrhotic liver or liver with inflammation. Thus, in the present study, we attempted to predict HCC prognosis by combining both liver function and expression of tumor markers. This approach involved the combination of the Child-Pugh score as liver function and the number of tumor markers expressed in HCC as tumor malignancy /2015 $
2 Table I. Patients background and clinicopathological findings of the study. Variable n=427 Sex (Male/Female) 350/77 Age 67 (30-83) Etiology (HBV/HCV/NBNC/HBV+HCV) 109/195/113/10 Child-Pugh Classification (A/B) 353/74 Albumin 3.9 ( ) Total bilirubin 0.8 ( ) Prothrombin activity 91 ( ) PLT( 10 4 /mm 3 ) 14.0 ( ) ICG R15 (%) 12.7 ( ) Number of tumors; median (range) 1 (1-9) Single/Multiple 274/153 Tumor size (cm) 3.5 (1.0-20) Macroscopic vascular invasion (-/+) 372/55 Microscopic vascular invasion (-/+) 206/221 Differentiation (well-mod/include poor) 327/100 Growth pattern (expansive/infiltrative) 286/41 AFP (ng/ml); median (range) 16.4 ( ) 20 ng/ml/<20 ng/ml 206/221 AFP-L3 (%); median (range) 0.5 ( ) 10 %/<10 % 117/310 DCP (mau/ml); median (range) 80 ( ) 40 mau/ml/<40 mau/ml 268/159 Liver resection (Anatomical/Non-anatomical) 279/148 Treatment for HCC (initial/non-initial) 119/308 HBV, Hepatitis B virus; HCV, hepatitis C virus; NBNC, non-b non-c; PLT, platelet count; ICG R15, Indocyanine Green Retention rate at 15 min; AFP; alpha-fetoprotein; AFP-L3, Lens culinaris agglutinin-reactive fraction of AFP; DCP, des-γ -carboxyprothrombin. Patients and Methods Patients and diagnosis. The study population consisted of 427 HCC patients who underwent curative hepatic resection at the Department of Gastroenterological Surgery, Kumamoto University Hospital, between January 2001 and May The patients underwent imaging studies, such as ultrasonography, dynamic CT and enhanced MRI, as well as CT angiography for diagnosis and staging of HCC before surgery. The final diagnosis was confirmed pathologically in the resected specimens. The severity of liver disease (liver fibrosis staging and hepatitis activity grading) was also evaluated according to the criteria proposed by the Inuyama classification (19). This was a retrospective, non-interventional, observational study, approved by the institutional ethics committee of Kumamoto University Hospital and performed in accordance with the Helsinki Declaration of Written informed consent was obtained from all patients. Measurement of hepatocellular carcinoma tumor markers. AFP, AFP-L3 and DCP were measured immediately before hepatic resection. The serum AFP level was determined by a chemiluminescent enzyme immunoassay (Siemens Immulite AFP IV; Mitsubishi Chemical Medience, Tokyo, Japan) and the serum AFP-L3 level was expressed as a percentage of the total AFP (AFP- L3/ total AFP 100) by lectin affinity electrophoresis coupled with antibody-affinity blotting (AFP-L3 Test Wako; Wako Pure Chemical Industries Ltd., Osaka, Japan). Serum DCP was determined by a chemiluminescent enzyme immuno assay (Lumipulse PIVKA-II Eisai; Eisai, Tokyo, Japan). The upper limits of the normal range of AFP, AFPL3 and DCP in our institution were 20 ng/ml, 10 % and 40 mau/ml, respectively. Tumor markers higher than the upper limit of the normal range were defined as positive. Treatment and surveillance. The surgical procedure was selected based on the tumor location, extent of the tumor, parenchymal liver function and the patients' general condition. Hepatic resection (HR) was considered as the first choice treatment for patients with good liver functional reserve (20). If the liver function allowed, anatomical resection was employed. The reasons for undergoing radiofrequency risk associated with general condition and refusal of HR. The follow-up program included AFP, AFP-L3 and DCP assays every 1-2 months, as well as ultrasonography, dynamic CT or dynamic MRI every 3-4 months after surgery. When a recurrence of HCC was detected, patients received further treatment for HCC, such as repeated hepatectomy, ablation therapy or trans-arterial chemoembolization (TACE). After treatment for recurrent lesions, the same surveillance was continued. Table II. The weight of number of positive tumor markers and Child-Pugh score for predicting overall survival. Univariate analysis Multivariate analysis RR 95%CI p-value RR 95%CI p-value β-value Number of positive tumor markers ** ** < *** < *** Child-Pugh classification A 1 1 B RR, Relative risk; CI, confidence interval. * p<0.05, ** p<0.01, *** p<
3 Nakagawa et al: Staging Based on Tumor Marker and Child-Pugh Table III. Tumor marker staging classification. Parameter/score Number of positive tumor markers 0 1 or 2 3 Child-Pugh stage A B Statistical analysis. Dichotomous variables were compared using the χ 2 test, where as continuous variables were compared using t-tests. The univariate and multivariate analysis based on the Cox regression model was used to estimate risk factors related to recurrence-free survival (RFS) and overall survival (OS), continuous variables were converted into binary. All p values of <0.05 were considered to be significant. The stepwise Cox regression model was used to provide the coefficient for Child-Pugh classification and the number of tumor markers. All analyses were performed using the JMP program (SAS Institute, Cary, NC, USA). Results Patients characteristics. Table I shows the patients background and clinicopathological characteristics of this study. Among the 427 patients, there were 350 men and 77 women ranging in age from years. More than three quarters (82.7%) of the patients belonged to Child-Pugh class A and 17.3% belonged to class B. The median values of serum AFP, AFP-L3 and DCP levels were 16.4 ng/ml, less than 0.5% and 80.0 mau/ml, respectively. Serum AFP, AFP-L3 and DCP levels over the upper limits of normal range were observed in 48.2% of the patients, 27.4% and 62.8%, respectively. Univariate analysis of the perioperative risk factors associated with recurrence rate and overall survival. The recurrence rates of all patients at 1, 3 and 5 years were 32.1, 60.3 and 77.0%, while the OS rates at 1, 3 and 5 years were 90.6, 72.0 and 64.8%. Multivariate analysis revealed that low serum albumin level (relative risk (RR)=1.49, p=0.0084), decreased platelet (PLT) count (RR=1.51, p=0.0086), multiple tumor (RR=1.93, p<0.0001) and tumor size >3.5cm (RR=1.55, p=0.0034) were the independent risk factors to predict high recurrence rate. Low serum albumin (RR=1.72, p=0.0163), multiple tumor (RR=1.62, p=0.0232) and tumor size >3.5cm (RR=2.28, p=0.0002) were the independent risk factors for poor OS by multivariate analysis. Coefficient weighting of tumor markers and Child-Pugh classification for predicting overall survival and newlyproposed prognostic scoring system; Tumor Marker Score (TMS) Stage. Table II shows the univariate and multivariate analysis of the number of tumor markers and Child-Pugh classification for OS and coefficient score (β value). The number of tumor markers and Child Pugh classification showed various scores that ranged from 0-2 of the Cox regression model, which is a rounded value based on 10 coefficients (Table III). Then, we added each score and classified HCC patients into four levels, thus establishing TMS stages 0 to 3. In each stage, recurrence rates at 1, 3 and 5 years were as follows: 14.9, 47.9 and 76.7% in TMS stage 0; 34.1, 58.7 and 72.3% in TMS stage 1; 39.9, 64.5 and 80.9% in TMS stage 2; and 63.9, 82.0 and 100% in TMS stage 3. OS in each stage was as follows: 99.7, 83.0 and 77.0% in TMS stage 0; 95.1, 76.5 and 68.7% in TMS stage 1; 79.6, 59.6 and 51.2% in TMS stage 2; and 53.9, 28.9 and 28.9% in TMS stage 3. The Kaplan-Meyer curves are shown in Figure 1. Comparison of scoring systems. The Kaplan-Meier survival curves for recurrence and OS by the TMS staging, number of tumor markers and CLIP scoring system are shown in Figures 1-3, respectively. The RRs for recurrence of TMS stage 0, 1, 2 and 3 are 1, 1.30, 1.92 and As shown in Table IVa, the RRs of only the number of tumor markers 0, 1, 2 and 3 are 1, 1.26, 2.53 and The RRs of CLIP 0 1, 2 and 3-5 are 1, 1.47, 2.51 and Of note about OS, as shown in Tabke IVb, the RR of CLIP 0. 1, 2, and 3-5 are 1, 2.53, 3.00 and The RR of only the number of tumor markers 0, 1, 2 and 3 are 1, 1.33, 2.27 and The RR for OS of TMS staging are 1, 1.41, 2.66 and Discussion AFP is the most widely used tumor marker for HCC and its high serum levels correlate with poor prognosis (21-28) and, as we have previously reported, the doubling time of preoperative AFP is a significant predictor for both DFS and OD (10). AFP-L3-positive status has been demonstra - ted to correlate with a large number of HCC tumors or those with a high malignant potential (7). A high level of serum DCP was reported to correlate with portal vein invasion and indicates a poor prognosis in HCC patients (25, 29). An elevated preoperative DCP has been demonstrated to be associated with a high recurrence rate after liver transplantation (30-32). However, the efficacies of preoperative levels of each tumor marker were not clear in the present study. Recently, the utility of the combined measurement of these three tumor markers (AFP, AFP-L3 and DCP) was demonstrated in predicting the outcome and recurrence for HCC patients treated with HR (11, 12). As we previously discussed (13), tumor markers evaluated before and after HR are used in these studies and examining their levels and postoperative levels seems imperative. However, predicting the patients prognosis before surgery is very important because we can choose the appropriate treatment modality based on the patient s own prognostic profile. Therefore, in this study, we attempted to predict prognosis by using only preoperative parameters. 2159
4 Table IVa. Comparison of the relative risk for recurrence of each classification. CLIP Number of tumor markers TMS Score RR p-value Number RR p-value Stage RR p-value * < *** * ** < *** ** * CLIP, Cancer of the liver Italian program; TMS, tumor marker staging; RR, relative risk. * p<0.05, ** p<0.01, *** p< Table IVb. Comparison of the relative risk for OS of each classification. CLIP Number of tumor markers TMS Score RR p-value Number RR p-value Stage RR p-value * *** ** *** < *** < *** < *** OS, Overall survival; CLIP, Cancer of the Liver Italian Program; TMS, tumor marker staging; RR, relative risk. * p<0.05, ** p<0.01, *** p< Figure 1. Recurrence rate and overall survival curves according to the TMS staging are shown. p-values and relative risk are shown in table IVa and b. Bruinx et al. reviewed that four main factors affect the prognosis of patients with HCC: (i) tumor characteristics, such as stage, aggressiveness and growth rate of the tumor; (ii) general health; (iii) liver function; and (iv) specific intervention. We considered the number of positive tumor markers as tumor characteristics and the Child-Pugh score as a liver function status. The staging system to estimate the patients prognosis is simple and based on factors that are easy to collect and should be constant between each participating institution. The herein presented TMS system can be calculated only from laboratory data and patient interview without any means of diagnostic imaging. The TMS system is also based on the cutoff line as a standard value and, therefore, it is universally useful if the measuring procedure is different between each institute even if cut-off values were different between several hospitals. 2160
5 Nakagawa et al: Staging Based on Tumor Marker and Child-Pugh Figure 2. Recurrence rate and overall survival curves according to the number of positive tumor markers are shown. p-values and relative risk are shown in table IVa and b. Figure 3. Recurrence rate and overall survival curves according to the CLIP score are shown. p-values and relative risk are shown in table IVa and b. In the present study, we created a new tumor marker staging (TMS) system that combines the number of positive tumor markers, as well as the Child-Pugh classification and is compared with the number of positive tumor markers and CLIP scoring system. The CLIP score was organized by variables that are examined for the HCC diagnosis routinely and based on laboratory data, Child-Pugh classification and imaging studies. The TMS system shows a similar or better analysis power compared with the CILP score for predicting RFS and OS of HCC patients after HR, even though TMS does not contain any imaging evaluation. Compared with the number of tumor markers only, TMS also exhibited better analysis power. However, it is clinically necessary to evaluate imaging findings for an in-depth look at diagnosis for decision-making on treatment for HCC patients, especially in the planning of surgical resection. Useful ways for further classification, in addition to imaging findings, include TMN, Okuda, BCLC and JIS staging (17, 33, 34). These staging systems favor prediction of prognosis of HCC patients with or without surgery and, in fact, many reports have shown their usefulness and the availability of other systems as well (17, 33-37). However, there exist some points to be improved as these systems do not include the measurement of biological factors, such as tumor markers. Sometimes, however, imaging findings do not reflect the gravity of the malignancy. It has been reported that it is difficult to 2161
6 diagnose small intrahepatic metastasis or microscopic portal vein invasion correctly by imaging features alone, especially when the tumors are small (29, 38). A few papers have confirmed that tumor markers are useful to predict the pathological malignancy of the HCC tumor, such as micro - vascular invasion or poor differentiation (11, 13). In order to evaluate tumor malignancy, including intrahepatic metastasis or microvascular invasion, it appears better to evaluate the positivity of tumor markers in addition to the staging systems based on imaging findings. In the present study, we showed that the TMS system was useful to predict the RFS and OS of HCC patients who underwent curative surgery. Its effectiveness should be validated in relation with the other staging systems currently employed and based on diagnostic imaging findings. References 1 Shaw JJ and Shah SA: Rising incidence and demographics of hepatocellular carcinoma in the USA: what does it mean? Expert Rev Gastroenterol Hepatol 5: , Bosch FX, Ribes J and Diaz Mand Cleries R: Primary liver cancer: world wide incidence and trends. Gastroenterology 127: S5-S16, Arii S, Yamaoka Y, Futagawa S, Inoue K, Kobayashi K, Kojiro M, Makuuchi M, Nakamura Y and Okita Kand Yamada R: Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology 32: , Tanaka S, Noguchi N, Ochiai T, Kudo A, Nakamura N, Ito K, Kawamura T and Teramoto Kand Arii S: Outcomes and recurrence of initially resectable hepatocellular carcinoma meeting milan criteria: Rationale for partial hepatectomy as first strategy. J Am Coll Surg 204: 1-6, Kamiyama T, Nakanishi K, Yokoo H, Kamachi H, Tahara M, Suzuki T, Shimamura T, Furukawa H and Matsushita Mand Todo S: Recurrence patterns after hepatectomy of hepatocellular carcinoma: implication of Milan criteria utilization. Ann Surg Oncol 16: , Fujiki M, Takada Y, Ogura Y, Oike F, Kaido T and Teramukai Sand Uemoto S: Significance of des-gamma-carboxy prothrombin in selection criteria for living donor liver transplantation for hepatocellular carcinoma. Am J Transplant 9: , Kumada T, Nakano S, Takeda I, Kiriyama S, Sone Y, Hayashi K, Katoh H, Endoh T and Sassa Tand Satomura S: Clinical utility of Lens culinaris agglutinin-reactive alpha-fetoprotein in small hepatocellular carcinoma: special reference to imaging diagnosis. J Hepatol 30: , Kobayashi M, Hosaka T, Ikeda K, Seko Y, Kawamura Y, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Saitoh S and Arase Yand Kumada H: Highly sensitive AFP-L3% assay is useful for predicting recurrence of hepatocellular carcinoma after curative treatment pre- and postoperatively. Hepatol Res 41: , Sakaguchi T, Suzuki S, Morita Y, Oishi K, Suzuki A, Fukumoto K, Inaba K and Nakamura Sand Konno H: Impact of the preopera tive des-gamma-carboxy prothrombin level on prognosis after hepatectomy for hepatocellular carcinoma meeting the Milan criteria. Surg Today 40: , Masuda T, Beppu T, Horino K, Komori H, Hayashi H, Okabe H, Otao R, Horlad H, Ishiko T, Takamori H and Kikuchi Kand Baba H: Preoperative tumor marker doubling time is a useful predictor of recurrence and prognosis after hepatic resection of hepatocellular carcinoma. J Surg Oncol 102: , Kiriyama S, Uchiyama K, Ueno M, Ozawa S, Hayami S and Tani Mand Yamaue H: Triple positive tumor markers for hepatocellular carcinoma are useful predictors of poor survival. Ann Surg 254: , Toyoda H, Kumada T, Tada T, Niinomi T, Ito T and Kaneoka Yand Maeda A: Prognostic significance of a combination of preand post-treatment tumor markers for hepatocellular carcinoma curati vely treated with hepatectomy. J Hepatol 57: , Nakagawa S, Beppu T, Okabe H, Sakamoto K, Kuroki H, Mima K, Nitta H, Imai K, Hayashi H, Sakamoto Y, Hashimoto D, Chikamoto A, Ishiko T and Watanabe Mand Baba H: Triple positive tumor markers predict recurrence and survival in early stage hepatocellular carcinoma. Hepatol Res Sobin LH and Fleming ID: TNM Classification of Malignant Tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer 80: , A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 28: , Takanishi DM, Jr. and Severino Rand Wong LL: The Cancer of the Liver Italian Program (CLIP) score: validation of a new prog nostic system for hepatocellular carcinoma. Hawaii Med J 66: , Kudo M and Chung Hand Osaki Y: Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limita tions, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol 38: , Yamakado K, Miyayama S, Hirota S, Mizunuma K, Nakamura K, Inaba Y, Maeda H, Matsuo K, Nishida N, Aramaki T, Anai H, Koura S, Oikawa S, Watanabe K, Yasumoto T and Furuichi Kand Yamaguchi M: Subgrouping of intermediate-stage (BCLC stage B) hepatocellular carcinoma based on tumor number and size and Child-Pugh grade correlated with prog nosis after transarterial chemoembolization. Jpn J Radiol 32: , Bedossa P and Poynard T: An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 24: , Imai K, Beppu T, Chikamoto A, Doi K, Okabe H, Hayashi H, Nitta H, Ishiko T and Takamori Hand Baba H: Comparison between hepatic resection and radiofrequency ablation as firstline treatment for solitary small-sized hepatocellular carcinoma of 3 cm or less. Hepatol Res 43: , Fujioka M, Nakashima Y and Nakashima Oand Kojiro M: Immu no histologic study on the expressions of alpha-fetoprotein and pro tein induced by vitamin K absence or antagonist II in surgi cally resected small hepatocellular carcinoma. Hepatology 34: , Adachi E, Maehara S, Tsujita E, Taguchi K, Aishima S, Rikimaru T and Yamashita Yand Tanaka S: Clinicopathologic risk factors for recurrence after a curative hepatic resection for hepatocellular carcinoma. Surgery 131: S ,
7 Nakagawa et al: Staging Based on Tumor Marker and Child-Pugh 23 Hanazaki K, Kajikawa S, Koide N and Adachi Wand Amano J: Prognostic factors after hepatic resection for hepatocellular carcinoma with hepatitis C viral infection: univariate and multivariate analysis. Am J Gastroenterol 96: , Yamanaka J, Yamanaka N, Nakasho K, Tanaka T, Ando T, Yasui C, Kuroda N, Takata M, Maeda S, Matsushita K and Uematsu Kand Okamoto E: Clinicopathologic analysis of stage II-III hepato cellular carcinoma showing early massive recurrence after liver resection. J Gastroenterol Hepatol 15: , Toyoda H, Kumada T, Kiriyama S, Sone Y, Tanikawa M, Hisanaga Y, Yamaguchi A, Isogai M and Kaneoka Yand Washizu J: Prognostic significance of simultaneous measurement of three tumor markers in patients with hepatocellular carcinoma. Clin Gastroenterol Hepatol 4: , Farinati F, Marino D, De Giorgio M, Baldan A, Cantarini M, Cursaro C, Rapaccini G, Del Poggio P, Di Nolfo MA, Benvegnu L, Zoli M, Borzio F and Bernardi Mand Trevisani F: Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither? Am J Gastroenterol 101: , Tangkijvanich P, Anukulkarnkusol N, Suwangool P, Lertmaharit S, Hanvivatvong O and Kullavanijaya Pand Poovorawan Y: Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels. J Clin Gastro enterol 31: , Yano Y, Yamashita F, Kuwaki K, Fukumori K, Kato O, Yamamoto H, Ando E and Tanaka Mand Sata M: Clinical features of hepatitis C virus-related hepatocellular carcinoma and their association with alpha-fetoprotein and protein induced by vitamin K absence or antagonist-ii. Liver Int 26: , Koike Y, Shiratori Y, Sato S, Obi S, Teratani T, Imamura M, Yoshida H and Shiina Sand Omata M: Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients. Cancer 91: , Shirabe K, Itoh S, Yoshizumi T, Soejima Y, Taketomi A and Aishima Sand Maehara Y: The predictors of microvascular invasion in candidates for liver transplantation with hepato cellular carci noma-with special reference to the serum levels of desgamma-carboxy prothrombin. J Surg Oncol 95: , Soejima Y, Taketomi A, Yoshizumi T, Uchiyama H, Aishima S, Terashi T and Shimada Mand Maehara Y: Extended indication for living donor liver transplantation in patients with hepatocellular carcinoma. Transplantation 83: , Takada Y, Ito T, Ueda M, Sakamoto S, Haga H, Maetani Y, Ogawa K, Ogura Y, Oike F and Egawa Hand Uemoto S: Living donor liver transplantation for patients with HCC exceeding the Milan criteria: a proposal of expanded criteria. Dig Dis 25: , Zhang JF, Shu ZJ, Xie CY, Li Q, Jin XH, Gu W and Jiang FJand Ling CQ: Prognosis of unresectable hepatocellular carcinoma: comparison of seven staging systems (TNM, Okuda, BCLC, CLIP, CUPI, JIS, CIS) in a Chinese cohort. PLoS One 9: e88182, Kudo M, Chung H, Haji S, Osaki Y, Oka H, Seki T, Kasugai H, and Sasaki Yand Matsunaga T: Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score. Hepatology 40: , Utsunomiya T, Shimada M, Kudo M, Ichida T, Matsui O, Izumi N, Matsuyama Y, Sakamoto M, Nakashima O, Ku Y and Kokudo N, Makuuchi Mand Liver Cancer Study Group of J: Nationwide study of 4741 patients with non-b non-c hepatocellular carcinoma with special reference to the therapeutic impact. Ann Surg 259: , Kudo M: Real practice of hepatocellular carcinoma in Japan: conclusions of the Japan Society of Hepatology 2009 Kobe Congress. Oncology 78 Suppl 1: , Marrero JA and Kudo Mand Bronowicki JP: The challenge of prognosis and staging for hepatocellular carcinoma. Oncologist 15 Suppl 4: 23-33, Yamashita F, Tanaka M and Satomura Sand Tanikawa K: Prognostic significance of Lens culinaris agglutinin A-reactive alpha-fetoprotein in small hepatocellular carcinomas. Gastroente - rology 111: , Received December 12, 2014 Revised January 12, 2015 Accepted January 16,
Triple positive tumor markers predict recurrence and survival in early stage hepatocellular carcinoma
See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/25864747 Triple positive tumor markers predict recurrence and survival in early stage hepatocellular
More informationPrognostic Significance of Simultaneous Measurement of Three Tumor Markers in Patients With Hepatocellular Carcinoma
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2006;4:111 117 Prognostic Significance of Simultaneous Measurement of Three Tumor Markers in Patients With Hepatocellular Carcinoma HIDENORI TOYODA,* TAKASHI KUMADA,*
More informationAlpha-Fetoprotein-L3 for Detection of Hepatocellular (Liver) Cancer. Original Policy Date
MP 2.04.35 Alpha-Fetoprotein-L3 for Detection of Hepatocellular (Liver) Cancer Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature
More informationThe Predictive Power of Serum α-fetoprotein and Des-γ-Carboxy Prothrombin for Survival Varies by Tumor Size in Hepatocellular Carcinoma
Kobe J. Med. Sci., Vol. 61, No. 5, pp. E124-E131, 2015 The Predictive Power of Serum α-fetoprotein and Des-γ-Carboxy Prothrombin for Survival Varies by Tumor Size in Hepatocellular Carcinoma DAISUKE TSUGAWA
More information간암의다양한병기분류법 : 현재사용중인병기분류를중심으로. Kim, Beom Kyung
간암의다양한병기분류법 : 현재사용중인병기분류를중심으로 Kim, Beom Kyung Importance of staging system 환자의예후예측 적절한치료방법적용 ( 수술, 방사선, 항암..) 의료진간의 tumor burden 에대한적절한의사소통 향후연구및 clinical trial 시연구집단의성격에대한객관적기준제시 Requisites for good staging
More informationSurvival outcomes of hepatectomy for stage B Hepatocellular carcinoma in the BCLC classification
Kamiyama et al. World Journal of Surgical Oncology (2017) 15:156 DOI 10.1186/s12957-017-1229-x RESEARCH Open Access Survival outcomes of hepatectomy for stage B Hepatocellular carcinoma in the BCLC classification
More informationCancer Medicine. Introduction. Open Access ORIGINAL RESEARCH
Cancer Medicine ORIGINAL RESEARCH Open Access Changes in highly sensitive alpha-fetoprotein for the prediction of the outcome in patients with hepatocellular carcinoma after hepatectomy Hidenori Toyoda
More informationcarcinoma at a single Japanese Inst Citation Hepato-Gastroenterology, 56(91-92),
NAOSITE: Nagasaki University's Ac Title Author(s) Treatment of concomitant gastric va carcinoma at a single Japanese Inst Nanashima, Atsushi; Sumida, Yorihis Kenichirou; Tomoshige, Kouichi; Tak Fukuoka,
More informationSerological and histological indices of hepatocellular carcinoma and tumor volume doubling time
MOLECULAR AND CLINICAL ONCOLOGY 1: 977-981, 2013 Serological and histological indices of hepatocellular carcinoma and tumor volume doubling time NAOKI SHINGAKI, HIDEYUKI TAMAI, YOSHIYUKI MORI, KOSAKU MORIBATA,
More informationSurvival Benefit of Locoregional Treatment for Hepatocellular Carcinoma with Advanced Liver Cirrhosis
2235-1795/16/0053-0175$39.50/0 175 Original Paper Survival Benefit of Locoregional Treatment for Hepatocellular Carcinoma with Advanced Liver Cirrhosis Satoshi Kitai a Masatoshi Kudo a Naoshi Nishida a
More informationThe most prominent etiological factors associated with hepatocellular
ORIGINAL ARTICLE A Comparison of the Surgical Outcomes Among Patients With -positive, -positive, and Non-B Non-C Hepatocellular Carcinoma A Nationwide Study of 11,95 Patients Tohru Utsunomiya, MD, PhD,
More informationSurveillance for Hepatocellular Carcinoma
Surveillance for Hepatocellular Carcinoma Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco Recorded on April
More informationONCOLOGY REPORTS 30: 91-98, 2013
ONCOLOGY REPORTS 30: 91-98, 2013 Lack of correlation between the antibody to hepatitis B core antigen and survival after surgical resection for hepatitis C virus-related hepatocellular carcinoma HIROKI
More informationMITSURU ISHIZUKA, KEIICHI KUBOTA, MITSUGI SHIMODA, JUNJI KITA, MASATO KATO, KYUNG HWA PARK and TAKAYUKI SHIRAKI
Effect of Menatetrenone, a Vitamin K 2 Analog, on Recurrence of Hepatocellular Carcinoma after Surgical Resection: A Prospective Randomized Controlled Trial MITSURU ISHIZUKA, KEIICHI KUBOTA, MITSUGI SHIMODA,
More informationComplete remission of advanced hepatocellular carcinoma following transient chemoembolization and portal vein ligation
Koga et al. Surgical Case Reports (2018) 4:102 https://doi.org/10.1186/s40792-018-0510-8 CASE REPORT Open Access Complete remission of advanced hepatocellular carcinoma following transient chemoembolization
More informationLiver resection for HCC
8 th LIVER INTEREST GROUP Annual Meeting Cape Town 2017 Liver resection for HCC Jose Ramos University of the Witwatersrand Donald Gordon Medical Centre The liver is almost unique in that treatment of the
More informationHepatocellular Carcinoma Surveillance
Amit G. Singal, MD, MS Hepatocellular Carcinoma Surveillance Postgraduate Course: Challenges in Management of Common Liver Diseases 308 1 Patient Case 69 year-old otherwise healthy male with compensated
More informationClinical Staging for Hepatocellular Carcinoma: Eastern Perspectives. Osamu Yokosuka, M.D. Graduate School of Medicine, Chiba University, Chiba, Japan
Clinical Staging for Hepatocellular Carcinoma: Eastern Perspectives Osamu Yokosuka, M.D. Graduate School of Medicine, Chiba University, Chiba, Japan Why is staging system important? Cancer stage can be
More informationComparison of the Outcomes of Hepatocellular Carcinoma Patients Following Local Ablation Therapy and Hepatectomy
Original Article Original Comparison of the Outcomes of Hepatocellular Carcinoma Patients Following Local Ablation Therapy and Kiyohide Kioka ) *, Takashi Nakai ), Yasuko Kawasaki ), Ayako Ueno 2), Yuhei
More informationAlthough hepatocellular carcinoma (HCC) with lymph node
ORIGINAL ARTICLE Impact of Histologically Confirmed Lymph Node Metastases on Patient Survival After Surgical Resection for Hepatocellular Carcinoma Report of a Japanese Nationwide Survey Kiyoshi Hasegawa,
More informationUsefulness of Resection for Hepatocellular Carcinoma with Macroscopic Bile Duct Tumor Thrombus
Usefulness of Resection for Hepatocellular Carcinoma with Macroscopic Bile Duct Tumor Thrombus ATSUSHI OBA 1, SHINICHIRO TAKAHASHI 1, YUICHIRO KATO 1, NAOTO GOTOHDA 1, TAKAHIRO KINOSHITA 1, HIDEHITO SHIBASAKI
More informationHeterogeneity and Subclassification of Barcelona Clinic Liver Cancer Stage B
2235-1795/16/0052-0091$39.50/0 91 Editorial Heterogeneity and Subclassification of Barcelona Clinic Liver Cancer Stage B Prof. M. Kudo Editor Liver Cancer Intermediate-stage hepatocellular carcinoma (HCC)
More informationEarly detection and characterization of hepatocellular. Early Detection and Curative Treatment of Early-Stage Hepatocellular Carcinoma
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2005;3:S144 S148 Early Detection and Curative Treatment of Early-Stage MASATOSHI KUDO Department of Gastroenterology and Hepatology, Kinki University School of
More informationONCOLOGY LETTERS 5: , 2013
ONCOLOGY LETTERS 5: 149-154, 2013 Epithelial-mesenchymal transition expression profiles as a prognostic factor for disease-free survival in hepatocellular carcinoma: Clinical significance of transforming
More informationOriginal Article. Comparison of 7 staging systems in north Indian cohort of hepatocellular carcinoma
Tropical Gastroenterology 2010;31(4):271 278 Original Article Comparison of 7 staging systems in north Indian cohort of hepatocellular carcinoma *Sanjay Sarma 1, *Balkrishan Sharma 1, Yogesh Kumar Chawla
More informationCorrespondence should be addressed to Toshimi Kaido;
Disease Markers Volume 215, Article ID 425926, 7 pages http://dx.doi.org/1.1155/215/425926 Research Article Long-Term Outcomes of Hepatic Resection versus Living Donor Liver Transplantation for Hepatocellular
More informationTakahito Nakagawa, MD, Toshiya Kamiyama, MD, Kazuaki Nakanishi, MD, Hideki Yokoo, MD, Hirofumi Kamachi, MD, Michiaki Matsushita, MD, Satoru Todo, MD
Pulmonary for metastases from hepatocellular carcinoma: Factors influencing prognosis Takahito Nakagawa, MD, Toshiya Kamiyama, MD, Kazuaki Nakanishi, MD, Hideki Yokoo, MD, Hirofumi Kamachi, MD, Michiaki
More informationNomograms to Predict the Disease-free Survival and Overall Survival after Radiofrequency Ablation for Hepatocellular Carcinoma
doi: 10.2169/internalmedicine.9064-17 Intern Med Advance Publication http://internmed.jp ORIGINAL ARTICLE Nomograms to Predict the Disease-free Survival and Overall Survival after Radiofrequency Ablation
More informationOver the past 20 years, great progress has been made in the
ORIGINAL ARTICLES Staging of Hepatocellular Carcinoma Assessment of the Japanese TNM and AJCC/UICC TNM Systems in a Cohort of 13,772 Patients in Japan Masami Minagawa, MD, PhD,* Iwao Ikai, MD, PhD,* Yutaka
More informationRisk factors of early recurrence after curative hepatectomy in hepatocellular carcinoma
720863TUB0010.1177/1010428317720863Tumor BiologyHong et al. research-article20172017 Original Article Risk factors of early recurrence after curative hepatectomy in hepatocellular carcinoma Tumor Biology
More informationHepatocellular Carcinoma. Markus Heim Basel
Hepatocellular Carcinoma Markus Heim Basel Outline 1. Epidemiology 2. Surveillance 3. (Diagnosis) 4. Staging 5. Treatment Epidemiology of HCC Worldwide, liver cancer is the sixth most common cancer (749
More informationExtending Indication: Role of Living Donor Liver Transplantation for Hepatocellular Carcinoma
LIVER TRANSPLANTATION 13:S48-S54, 27 SUPPLEMENT Extending Indication: Role of Living Donor Liver Transplantation for Hepatocellular Carcinoma Satoru Todo, 1 Hiroyuki Furukawa, 2 Mitsuhiro Tada, 3 and the
More informationEASL-EORTC Guidelines
Pamplona, junio de 2008 CLINICAL PRACTICE GUIDELINES: PARADIGMS IN MANAGEMENT OF HCC EASL-EORTC Guidelines Bruno Sangro Clínica Universidad de Navarra. CIBERehd. Pamplona, Spain Levels of Evidence according
More informationHow to apply HCC prediction models to practice?
How to apply HCC prediction models to practice? Department of Internal Medicine, Keimyung University School of Medicine Woo Jin Chung HCC prediction models 독특하게간세포암환자들의생존은암의진행상태뿐아니라기저간기능의중증정도에영향을받는특성이있다.
More informationCelsion Symposium New Paradigms in HCC Staging: HKLC vs. BCLC Staging
Celsion Symposium New Paradigms in HCC Staging: HKLC vs. BCLC Staging Ronnie T.P. Poon, MBBS, MS, PhD Chair Professor of Hepatobiliary and Pancreatic Surgery Chief of Hepatobiliary and Pancreatic Surgery
More informationLong-term prognosis after resection of cryptogenic hepatocellular carcinoma
Ohkura et al. BMC Surgery (2015) 15:115 DOI 10.1186/s12893-015-0099-9 RESEARCH ARTICLE Open Access Long-term prognosis after resection of cryptogenic hepatocellular carcinoma Yu Ohkura *, Kazunari Sasaki,
More informationCombined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for. hepatocellular carcinoma in cirrhotic patients
Scandinavian Journal of Gastroenterology ISSN: 0036-5521 (Print) 1502-7708 (Online) Journal homepage: http://www.tandfonline.com/loi/igas20 Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances
More informationManagement of hepatocellular carcinoma should consider both tumor factors and background liver factors
Hepatocellular Carcinoma Column: Editorial Management of hepatocellular carcinoma should consider both tumor factors and background liver factors Shuji Nomoto, Mitsuhiro Hishida, Yoshikuni Inokawa, Hiroyuki
More informationLong-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance
Long-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance Gi-Ae Kim, Han Chu Lee *, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim,
More informationCorrelation analysis of preoperative serum alpha-fetoprotein (AFP) level and prognosis of hepatocellular carcinoma (HCC) after hepatectomy
Ma et al. World Journal of Surgical Oncology 2013, 11:212 WORLD JOURNAL OF SURGICAL ONCOLOGY RESEARCH Open Access Correlation analysis of preoperative serum alpha-fetoprotein (AFP) level and prognosis
More informationdoi: /hepr Response Evaluation Criteria in Cancer of the Liver (RECICL) (2015 Revised version)
bs_bs_banner Hepatology Research 2016; 46: 3 9 doi: 10.1111/hepr.12542 Special Report Response Evaluation Criteria in Cancer of the Liver (RECICL) (2015 Revised version) Masatoshi Kudo, Kazuomi Ueshima,
More informationManagement of HepatoCellular Carcinoma
9th Symposium GIC St Louis - 2010 Management of HepatoCellular Carcinoma Overview Pierre A. Clavien, MD, PhD Department of Surgery University Hospital Zurich Zurich, Switzerland Hepatocellular carcinoma
More informationClinical Practice Guidelines for Hepatocellular Carcinoma Differ between Japan, United States, and Europe
2235-1795/15/0042-0085$39.50/0 85 Editorial Clinical Practice Guidelines for Hepatocellular Carcinoma Differ between Japan, United States, and Europe Prof. M. Kudo Editor Liver Cancer Introduction Hepatocellular
More informationORIGINAL ARTICLES LIVER, PANCREAS, AND BILIARY TRACT
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2011;9:989 994 ORIGINAL ARTICLES LIVER, PANCREAS, AND BILIARY TRACT Level of -Fetoprotein Predicts Mortality Among Patients With Hepatitis C Related Hepatocellular
More informationUnmet needs in intermediate HCC. Korea University Guro Hospital Ji Hoon Kim
Unmet needs in intermediate HCC Korea University Guro Hospital Ji Hoon Kim BCLC HCC Stage 0 PST 0, Child Pugh A Stage A C PST 0 2, Child Pugh A B Stage D PST > 2, Child Pugh C Very early stage (0) 1 HCC
More informationHEPATOCELLULAR CARCINOMA: SCREENING, DIAGNOSIS, AND TREATMENT
HEPATOCELLULAR CARCINOMA: SCREENING, DIAGNOSIS, AND TREATMENT INTRODUCTION: Hepatocellular carcinoma (HCC): Fifth most common cancer worldwide Third most common cause of cancer mortality In Egypt: 2.3%
More informationXiang Hu*, Liang Cao*, Yi Yu. Introduction
Original Article Prognostic prediction in gastric cancer patients without serosal invasion: comparative study between UICC 7 th edition and JCGS 13 th edition N-classification systems Xiang Hu*, Liang
More informationDetection and Characterization of Hepatocellular Carcinoma by Imaging
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2005;3:S136 S140 Detection and Characterization of Hepatocellular Carcinoma by Imaging OSAMU MATSUI Department of Imaging Diagnosis and Interventional Radiology,
More informationGamal F. El Naggar (1), Eman A. Alzamarany (2)
Diagnostic value of Protein Induced by Vitamin K Absence or Antagonist - II (PIVIKA II) in patients with hepatocellular carcinoma (HCC): Comparison with alpha fetoprotein Gamal F. El Naggar (1), Eman A.
More informationNegative impact of low body mass index on liver cirrhosis patients with hepatocellular carcinoma
Li et al. World Journal of Surgical Oncology (2015) 13:294 DOI 10.1186/s12957-015-0713-4 WORLD JOURNAL OF SURGICAL ONCOLOGY RESEARCH Open Access Negative impact of low body mass index on liver cirrhosis
More informationALPHA-FETOPROTEIN-L3 FOR DETECTION OF HEPATOCELLULAR CANCER
Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs are dependent upon
More informationORIGINAL ARTICLE. Abstract. Introduction
ORIGINAL ARTICLE Prognosis of Patients with Hepatocellular Carcinoma Treated Solely with Transcatheter Arterial Chemoembolization: Risk Factors for One-year Recurrence and Two-year Mortality (Preliminary
More informationActual 10-year survival following hepatectomy for hepatocellular carcinoma
DOI:10.1111/hpb.12206 HPB ORIGINAL ARTICLE Actual 10-year survival following hepatectomy for hepatocellular carcinoma Bernardo Franssen, Ghalib Jibara, Parissa Tabrizian, Myron E. Schwartz & Sasan Roayaie
More informationPrognostic factors in patients with hepatitis B virus related hepatocellular carcinoma undergoing nucleoside analog antiviral therapy
ONCOLOGY LETTERS 6: 1213-1218, 2013 Prognostic factors in patients with hepatitis B virus related hepatocellular carcinoma undergoing nucleoside analog antiviral therapy HIROKI NISHIKAWA 1, NORIHIRO NISHIJIMA
More informationPrognostic Role of Gastrectomy in Patients With Gastric Cancer With Positive Peritoneal Cytology
Int Surg 2014;99:830 834 DOI: 10.9738/INTSURG-D-14-00119.1 Prognostic Role of Gastrectomy in Patients With Gastric Cancer With Positive Peritoneal Cytology Okihide Suzuki, Minoru Fukuchi, Erito Mochiki,
More informationMasuda et al. Surgical Case Reports (2015) 1:55 DOI /s y
Masuda et al. Surgical Case Reports (2015) 1:55 DOI 10.1186/s40792-015-0056-y CASE REPORT Repeated hepatic resections and radio-frequency ablations may improve the survival of adult undifferentiated embryonal
More informationPeri-Transplant Change in AFP Level: A Useful Predictor of Hepatocellular Carcinoma Recurrence Following Liver Transplantation
ORIGINAL ARTICLE Cell Therapy & Organ Transplantation http://dx.doi.org/1.3346/jkms.16.31.7.149 J Korean Med Sci 16; 31: 149-154 Peri-Transplant Change in AFP Level: A Useful Predictor of Hepatocellular
More informationSurveillance for HCC Who, how Diagnosis of HCC Surveillance for HCC in Practice
Surveillance for Hepatocellular Carcinoma Hashem B. El-Serag, MD, MPH Dan L. Duncan Professor of Medicine Chief, Gastroenterology and Hepatology Houston VA & Baylor College of Medicine Houston, TX Outline
More informationEarly disseminated recurrence after liver resection in solitary hepatocellular carcinoma
ORIGINAL ARTICLE pissn 2288-6575 eissn 2288-6796 https://doi.org/10.4174/astr.2018.94.3.129 Annals of Surgical Treatment and Research Early disseminated recurrence after liver resection in solitary hepatocellular
More informationStudy Objective and Design
Randomized, Open Label, Multicenter, Phase II Trial of Transcatheter Arterial Chemoembolization (TACE) Therapy in Combination with Sorafenib as Compared With TACE Alone in Patients with Hepatocellular
More informationStaging and prognostic systems: beyond BCLC?
Staging and prognostic systems: beyond BCLC? Alessandro Vitale, MD, PhD, FEBS U.O.C. di Chirurgia Epatobiliare e dei Trapianti Epatici, Department of Surgery, Oncology and Gastroenterology, University
More informationHepatocellular Carcinoma in Qatar
Hepatocellular Carcinoma in Qatar K. I. Rasul 1, S. H. Al-Azawi 1, P. Chandra 2 1 NCCCR, 2 Medical Research Centre, Hamad Medical Corporation, Doha, Qatar Abstract Objective The main aim of this study
More informationPrognostic factors after hepatic resection for the single hepatocellular carcinoma larger than 5 cm
ORIGINAL ARTICLE pissn 2288-6575 eissn 2288-6796 http://dx.doi.org/1174/astr.216.91.3.14 Annals of Surgical Treatment and Research Prognostic factors after hepatic resection for the single hepatocellular
More information: TP6.3 g dl, Alb4.3 g dl, GOT17 IU l, GPT26 IU l,
5 Vol. 34, pp. 5 23, 2006 C IFN 0 2 : 8 4 20 63 986 990 C 993 S7 C A F2 IFN IFNa2a 9MIU 24W HCV-RNA 995 2 F HCV-RNA IFN 0 2004 5 S8 20 mm CT SPIO-MRI 6 TP6.3 g dl, Alb4.3 g dl, GOT7 IU l, GPT26 IU l, g-gtp40
More informationCorrespondence should be addressed to Masanori Matsuda;
HPB Surgery, Article ID 641685, 8 pages http://dx.doi.org/10.1155/2014/641685 Clinical Study Preoperative Gadoxetic Acid-Enhanced MRI and Simultaneous Treatment of Early Hepatocellular Carcinoma Prolonged
More informationHepatocellular carcinoma in Sri Lanka - where do we stand?
SCIENTIFIC ARTICLE Hepatocellular carcinoma in Sri Lanka - where do we stand? R.C. Siriwardana 1, C.A.H. Liyanage 1, M.B. Gunethileke 2 1. Specialist Gastrointestinal and Hepatobilliary Surgeon, Senior
More informationSEQUENCING OF HCC TREATMENT. Dr. Amit G. Singal Medical Director, UT Southwestern Medical Center, USA
SEQUENCING OF HCC TREATMENT Dr. Amit G. Singal Medical Director, UT Southwestern Medical Center, USA February 2018 DISCLAIMER Please note: The views expressed within this presentation are the personal
More informationTumor Markers for Hepatocellular Carcinoma: Simple and Significant Predictors of Outcome in Patients with HCC
2235-1795/15/42-126$39.5/ 126 Review Tumor Markers for Hepatocellular Carcinoma: Simple and Significant Predictors of Outcome in Patients with HCC Hidenori Toyoda a Takashi Kumada a Toshifumi Tada a Yasuhiro
More informationHepatocellular carcinoma (HCC) is the most
Original Article / Biliary Hepatobiliary & Pancreatic Diseases International Prognosis of hepatocellular carcinoma with bile duct tumor thrombus after R0 resection: a matched study Ding-Ding Wang, Li-Qun
More informationLiver transplantation: Hepatocellular carcinoma
Liver transplantation: Hepatocellular carcinoma Alejandro Forner BCLC Group. Liver Unit. Hospital Clínic. University of Barcelona 18 de marzo 2015 3r Curso Práctico de Transplante de Órganos Sólidos Barcelona
More informationTwo Rare Metachronous Metastases of Hepatocellular Carcinoma After Liver Transplantation
Int Surg 2013;98:432 436 DOI: 10.9738/INTSURG-D-13-00026.1 Case Report Two Rare Metachronous Metastases of Hepatocellular Carcinoma After Liver Transplantation Satoshi Shinya 1, Tomoaki Noritomi 1, Yasushi
More informationNatural History and Treatment Trends in Hepatocellular Carcinoma Subtypes: Insights From a National Cancer Registry
2015;112:872 876 Natural History and Treatment Trends in Hepatocellular Carcinoma Subtypes: Insights From a National Cancer Registry PETER L. JERNIGAN, MD, KOFFI WIMA, MS, DENNIS J. HANSEMAN, PhD, RICHARD
More informationRESEARCH ARTICLE. Validation of The Hong Kong Liver Cancer Staging System in Patients with Hepatocellular Carcinoma after Curative Intent Treatment
DOI:10.22034/APJCP.2017.18.6.1697 RESEARCH ARTICLE Validation of The Hong Kong Liver Cancer Staging System in Patients with Hepatocellular Carcinoma after Curative Intent Treatment Alan Chuncharunee 1,
More informationPercutaneous Microwave Coagulation Therapy for Hepatocellular Carcinoma
Hiroshima J. Med. Sci. Vol. 47, No.4, 151~155, December, 1998 HIJM47-2 151 Percutaneous Microwave Coagulation Therapy for Hepatocellular Carcinoma Toshimasa ASAHARA1l, Hideki NAKAHARA1l, Toshikatsu FUKUDA1l,
More informationAtypically large well-differentiated hepatocellular carcinoma with extensive fatty metamorphosis : ReportofaCase
267 CASE REPORT Atypically large well-differentiated hepatocellular carcinoma with extensive fatty metamorphosis : ReportofaCase Daichi Ishikawa, Mitsuo Shimada, Tohru Utsunomiya, Yuji Morine, Satoru Imura,
More informationScreening for HCCwho,
Screening for HCCwho, how and how often? Catherine Stedman Associate Professor of Medicine, University of Otago, Christchurch Gastroenterology Department, Christchurch Hospital HCC Global Epidemiology
More informationPostoperative recurrence in hepatocellular carcinoma: Comparison between percutaneous ethanol injection and radiofrequency ablation
Hepatology Research 36 (2006) 143 148 Postoperative recurrence in hepatocellular carcinoma: Comparison between percutaneous ethanol injection and radiofrequency ablation Kaoru Iwata, Tetsuro Sohda, Shinya
More informationSelection of patients of hepatocellular carcinoma beyond the Milan criteria for liver transplantation
Title Selection of patients of hepatocellular carcinoma beyond the Milan criteria for liver transplantation Author(s) Chan, SC; Fan, ST Citation Hepatobiliary Surgery and Nutrition, 2013, v. 2 n. 2, p.
More informationOriginal Article The change of sicam-1 and PIVKA-II after treatment of hepatocellular carcinoma as a predictor of patient survival
Int J Clin Exp Med 2017;10(9):13746-13752 www.ijcem.com /ISSN:1940-5901/IJCEM0048426 Original Article The change of sicam-1 and PIVKA-II after treatment of hepatocellular carcinoma as a predictor of patient
More informationLiving donor liver transplantation for patients with hepatocellular carcinoma in Japan
Sugawara et al. Hepatoma Res 2018;4:33 DOI: 10.20517/2394-5079.2018.69 Hepatoma Research Review Open Access Living donor liver transplantation for patients with hepatocellular carcinoma in Japan Yasuhiko
More informationHepatocellular Carcinoma (HCC): Who Should be Screened and How Do We Treat? Tom Vorpahl MSN, RN, ACNP-BC
Hepatocellular Carcinoma (HCC): Who Should be Screened and How Do We Treat? Tom Vorpahl MSN, RN, ACNP-BC Objectives Identify patient risk factors for hepatocellular carcinoma (HCC) Describe strategies
More information6/16/2016. Treating Hepatocellular Carcinoma: Deciphering the Clinical Data. Liver Regeneration. Liver Regeneration
Treating : Deciphering the Clinical Data Derek DuBay, MD Associate Professor of Surgery Director of Liver Transplant Liver Transplant and Hepatobiliary Surgery UAB Department of Surgery Liver Regeneration
More informationSurgical resection for hepatocellular carcinoma (HCC)
Surgical resection for hepatocellular carcinoma (HCC) Wojciech G Polak, MD, PhD, FEBS Department of Surgery, Division of HPB and Transplant Surgery, Erasmus MC, University Medical Center Rotterdam the
More informationLung cancer is a major cause of cancer deaths worldwide.
ORIGINAL ARTICLE Prognostic Factors in 3315 Completely Resected Cases of Clinical Stage I Non-small Cell Lung Cancer in Japan Teruaki Koike, MD,* Ryosuke Tsuchiya, MD, Tomoyuki Goya, MD, Yasunori Sohara,
More informationRandomized clinical trial: Nucleos(t)ide analogues improved survival of CHB-related HCC patients via reducing severity and progression of malignancy
/, Vol. 7, No. 36 Randomized clinical trial: Nucleos(t)ide analogues improved survival of CHB-related HCC patients via reducing severity and progression of malignancy Yun Wang 1,*, Xiaogang Xiang 1,*,
More informationORIGINAL ARTICLE. Impact of Histological Grade of Hepatocellular Carcinoma on the Outcome of Liver Transplantation
ORIGINAL ARTICLE Impact of Histological Grade of Hepatocellular Carcinoma on the Outcome of Liver Transplantation Sumihito Tamura, MD; Tomoaki Kato, MD; Mariana Berho, MD; Evangelos P. Misiakos, MD; Christopher
More informationHepatocellular carcinoma (HCC) is a common. Prediction of Recurrence of Hepatocellular Carcinoma After Curative Ablation Using Three Tumor Markers
Prediction of Recurrence of Hepatocellular Carcinoma After Curative Ablation Using Three Tumor Markers Ryosuke Tateishi, Shuichiro Shiina, Haruhiko Yoshida, Takuma Teratani, Shuntaro Obi, Noriyo Yamashiki,
More informationHepatobiliary Malignancies Retrospective Study at Truman Medical Center
Hepatobiliary Malignancies 206-207 Retrospective Study at Truman Medical Center Brandon Weckbaugh MD, Prarthana Patel & Sheshadri Madhusudhana MD Introduction: Hepatobiliary malignancies are cancers which
More informationDiagnostic Utility of Alpha fetoprotein and Des gamma carboxyprothrombin in Nigerians with Hepatocellular Carcinoma
Original Article Diagnostic Utility of Alpha fetoprotein and Des gamma carboxyprothrombin in Nigerians with Hepatocellular Carcinoma Akpakip Ikpong Ette, DA Ndububa 1, O Adekanle 1, U Ekrikpo 2 Department
More informationLong-term outcome of percutaneous ethanol injection therapy for minimum-sized hepatocellular carcinoma
Online Submissions: wjg.wjgnet.com World J Gastroenterol 2008 April 7; 14(13): 1997-2002 World Journal of Gastroenterology ISSN 1007-9327 wjg@wjgnet.com 2008 WJG. All rights reserved. LIVER CANCER Long-term
More informationBile duct invasion can be an independent prognostic factor in early stage hepatocellular carcinoma
Korean J Hepatobiliary Pancreat Surg 2015;19:167-172 http://dx.doi.org/10.14701/kjhbps.2015.19.4.167 Original Article Bile duct invasion can be an independent prognostic factor in early stage hepatocellular
More informationPreoperative Chemolipiodolization of the Whole Liver for Hepatocellular Carcinoma
Preoperative Chemolipiodolization of the Whole Liver for Hepatocellular Carcinoma MASAKI KAIBORI 1, NOBORU TANIGAWA 2, YOICHI MATSUI 1, A-HON KWON 1, SATOSHI SAWADA 2 and YASUO KAMIYAMA 1 1 Department
More informationPEER-REVIEW REPORT CLASSIFICATION LANGUAGE EVALUATION SCIENTIFIC MISCONDUCT CONCLUSION. [ Y] Accept [ ] Grade B: Very good
Reviewer s code: 03656588 Reviewer s country: China Date reviewed: 2017-06-08 [ ] Grade A: Excellent [ Y] Accept [ ] Grade B: Very good [ ] High priority for [ Y] Grade C: Good language [ ] Major revision
More informationReview Article. Dig Dis 2015;33: DOI: /
Review Article General Rules for the Clinical and Pathological Study of Primary Liver Cancer, Nationwide Follow-Up Survey and Clinical Practice Guidelines: The Outstanding Achievements of the Liver Cancer
More informationMedicine. Infiltrative Hepatocellular Carcinoma. Assessment of Factors Associated With Outcomes in Patients Undergoing Hepatectomy
Medicine OBSERVATIONAL STUDY Infiltrative Hepatocellular Carcinoma Assessment of Factors Associated With Outcomes in Patients Undergoing Hepatectomy Xiaopeng Yan, MD, Xu Fu, MD, Min Deng, MM, Jun Chen,
More information21/02/2014. Disclosures. HCC: predicting recurrence. Outline. Liver transplant: Beyond Milan?
Disclosures HCC: predicting recurrence Peter Ghali, MD, FRCPC, MSc (epid) None relevant to this talk other than off-label use of sirolimus Toronto, February 2014 Outline Recurrence after what? Locoregional
More informationAkt Phosphorylation Is a Risk Factor for Early Disease Recurrence and Poor Prognosis in Hepatocellular Carcinoma
307 Akt Phosphorylation Is a Risk Factor for Early Disease Recurrence and Poor Prognosis in Hepatocellular Carcinoma Kazuaki Nakanishi, M.D., Ph.D. 1,2 Michiie Sakamoto, M.D., Ph.D. 1,3 Susumu Yamasaki,
More informationSurgical management of HCC. Evangelos Prassas Hepatobiliary and Pancreatic Surgery / Liver Transplantation Kings College Hospital / London
Surgical management of HCC Evangelos Prassas Hepatobiliary and Pancreatic Surgery / Liver Transplantation Kings College Hospital / London Global distribution of HCC and staging systems WEST 1. Italy (Milan,
More informationSignificance of Hepatectomy for AJCC/UICC T3 Hepatocellular Carcinoma
Significance of Hepatectomy for AJCC/UICC T3 Hepatocellular Carcinoma TOSHIYA OCHIAI 1,2, HIROMICHI ISHII 1, YUSUKE YAMAMOTO 2, RYO MORIMURA 2, HISASHI IKOMA 2 and EIGO OTSUJI 2 1 Department of Surgery,
More informationHepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary)
Hepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary) Staff Reviewers: Dr. Yoo Joung Ko (Medical Oncologist, Sunnybrook Odette Cancer
More information